These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 31911556)

  • 1.
    Santoro AL; Drummond RD; Silva IT; Ferreira SS; Juliano L; Vendramini PH; Lemos MBDC; Eberlin MN; Andrade VP
    Cancer Res; 2020 Mar; 80(6):1246-1257. PubMed ID: 31911556
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Extent of ductal carcinoma in situ according to breast cancer subtypes: a population-based cohort study.
    Doebar SC; van den Broek EC; Koppert LB; Jager A; Baaijens MHA; Obdeijn IAM; van Deurzen CHM
    Breast Cancer Res Treat; 2016 Jul; 158(1):179-187. PubMed ID: 27318854
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Invasive ductal carcinoma with coexisting ductal carcinoma in situ (IDC/DCIS) versus pure invasive ductal carcinoma (IDC): a comparison of clinicopathological characteristics, molecular subtypes, and clinical outcomes.
    Goh CW; Wu J; Ding S; Lin C; Chen X; Huang O; Chen W; Li Y; Shen K; Zhu L
    J Cancer Res Clin Oncol; 2019 Jul; 145(7):1877-1886. PubMed ID: 31089799
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prediction of coexisting invasive carcinoma on ductal carcinoma in situ (DCIS) lesions by mass spectrometry imaging.
    Chen H; Li X; Li F; Li Y; Chen F; Zhang L; Ye F; Gong M; Bu H
    J Pathol; 2023 Oct; 261(2):125-138. PubMed ID: 37555360
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Extracellular Microenvironment Alterations in Ductal Carcinoma In Situ and Invasive Breast Cancer Pathologies by Multiplexed Spatial Proteomics.
    Hulahan TS; Spruill L; Wallace EN; Park Y; West RB; Marks JR; Hwang ES; Drake RR; Angel PM
    Int J Mol Sci; 2024 Jun; 25(12):. PubMed ID: 38928454
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Progression-specific genes identified in microdissected formalin-fixed and paraffin-embedded tissue containing matched ductal carcinoma in situ and invasive ductal breast cancers.
    Schultz S; Bartsch H; Sotlar K; Petat-Dutter K; Bonin M; Kahlert S; Harbeck N; Vogel U; Seeger H; Fehm T; Neubauer HJ
    BMC Med Genomics; 2018 Sep; 11(1):80. PubMed ID: 30236106
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PIK3CA mutations in ductal carcinoma in situ and adjacent invasive breast cancer.
    Agahozo MC; Sieuwerts AM; Doebar SC; Verhoef EI; Beaufort CM; Ruigrok-Ritstier K; de Weerd V; Sleddens HFBM; Dinjens WNM; Martens JWM; van Deurzen CHM
    Endocr Relat Cancer; 2019 May; 26(5):471-482. PubMed ID: 30844755
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Profiling differential microRNA expression between in situ, infiltrative and lympho-vascular space invasive breast cancer: a pilot study.
    Soon PS; Provan PJ; Kim E; Pathmanathan N; Graham D; Clarke CL; Balleine RL
    Clin Exp Metastasis; 2018 Feb; 35(1-2):3-13. PubMed ID: 29214365
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discordant Marker Expression Between Invasive Breast Carcinoma and Corresponding Synchronous and Preceding DCIS.
    Visser LL; Elshof LE; Van de Vijver K; Groen EJ; Almekinders MM; Sanders J; Bierman C; Peters D; Hofland I; Broeks A; van Leeuwen FE; Rutgers EJT; Schmidt MK; Schaapveld M; Lips EH; Wesseling J
    Am J Surg Pathol; 2019 Nov; 43(11):1574-1582. PubMed ID: 31206365
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ductal carcinoma in situ and the emergence of diversity during breast cancer evolution.
    Allred DC; Wu Y; Mao S; Nagtegaal ID; Lee S; Perou CM; Mohsin SK; O'Connell P; Tsimelzon A; Medina D
    Clin Cancer Res; 2008 Jan; 14(2):370-8. PubMed ID: 18223211
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Subtypes of high-grade breast ductal carcinoma in situ (DCIS): incidence and potential clinical impact.
    Schandiz H; Park D; Kaiser YL; Lyngra M; Talleraas IS; Geisler J; Sauer T
    Breast Cancer Res Treat; 2023 Sep; 201(2):329-338. PubMed ID: 37453021
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of nuclear grade and immunohistochemical features in situ and invasive components of ductal carcinoma of breast.
    Aguiar FN; Mendes HN; Bacchi CE; Carvalho FM
    Rev Bras Ginecol Obstet; 2013 Mar; 35(3):97-102. PubMed ID: 23538467
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lipid Coverage in Nanospray Desorption Electrospray Ionization Mass Spectrometry Imaging of Mouse Lung Tissues.
    Nguyen SN; Kyle JE; Dautel SE; Sontag R; Luders T; Corley R; Ansong C; Carson J; Laskin J
    Anal Chem; 2019 Sep; 91(18):11629-11635. PubMed ID: 31412198
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Classification of ductal carcinoma in situ by gene expression profiling.
    Hannemann J; Velds A; Halfwerk JB; Kreike B; Peterse JL; van de Vijver MJ
    Breast Cancer Res; 2006; 8(5):R61. PubMed ID: 17069663
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ambient Lipidomic Analysis of Single Mammalian Oocytes and Preimplantation Embryos Using Desorption Electrospray Ionization (DESI) Mass Spectrometry.
    Ferreira CR; Pirro V; Jarmusch AK; Alfaro CM; Cooks RG
    Methods Mol Biol; 2020; 2064():159-179. PubMed ID: 31565774
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Emerging Roles of Steroid Hormone Receptors in Ductal Carcinoma in Situ (DCIS) of the Breast.
    Villanueva H; Grimm S; Dhamne S; Rajapakshe K; Visbal A; Davis CM; Ehli EA; Hartig SM; Coarfa C; Edwards DP
    J Mammary Gland Biol Neoplasia; 2018 Dec; 23(4):237-248. PubMed ID: 30338425
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Progression of ductal carcinoma in situ to invasive breast cancer: comparative genomic sequencing.
    Doebar SC; Krol NM; van Marion R; Brouwer RWW; van Ijcken WFJ; Martens JM; Dinjens WNM; van Deurzen CHM
    Virchows Arch; 2019 Feb; 474(2):247-251. PubMed ID: 30284611
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluating the Risk of Upstaging HER2-Positive DCIS to Invasive Breast Cancer.
    Mustafa RE; DeStefano LM; Bahng J; Yoon-Flannery K; Fisher CS; Zhang PJ; Tchou J; Czerniecki BJ; De La Cruz LM
    Ann Surg Oncol; 2017 Oct; 24(10):2999-3003. PubMed ID: 28766212
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular classification and biomarkers of clinical outcome in breast ductal carcinoma in situ: Analysis of TBCRC 038 and RAHBT cohorts.
    Strand SH; Rivero-Gutiérrez B; Houlahan KE; Seoane JA; King LM; Risom T; Simpson LA; Vennam S; Khan A; Cisneros L; Hardman T; Harmon B; Couch F; Gallagher K; Kilgore M; Wei S; DeMichele A; King T; McAuliffe PF; Nangia J; Lee J; Tseng J; Storniolo AM; Thompson AM; Gupta GP; Burns R; Veis DJ; DeSchryver K; Zhu C; Matusiak M; Wang J; Zhu SX; Tappenden J; Ding DY; Zhang D; Luo J; Jiang S; Varma S; Anderson L; Straub C; Srivastava S; Curtis C; Tibshirani R; Angelo RM; Hall A; Owzar K; Polyak K; Maley C; Marks JR; Colditz GA; Hwang ES; West RB
    Cancer Cell; 2022 Dec; 40(12):1521-1536.e7. PubMed ID: 36400020
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HER2 as a prognostic factor in breast cancer.
    Ménard S; Fortis S; Castiglioni F; Agresti R; Balsari A
    Oncology; 2001; 61 Suppl 2():67-72. PubMed ID: 11694790
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.